DE102004059357B8 - Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung - Google Patents

Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung Download PDF

Info

Publication number
DE102004059357B8
DE102004059357B8 DE102004059357A DE102004059357A DE102004059357B8 DE 102004059357 B8 DE102004059357 B8 DE 102004059357B8 DE 102004059357 A DE102004059357 A DE 102004059357A DE 102004059357 A DE102004059357 A DE 102004059357A DE 102004059357 B8 DE102004059357 B8 DE 102004059357B8
Authority
DE
Germany
Prior art keywords
ligands
interaction
antibody blocking
human thy
thy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE102004059357A
Other languages
English (en)
Other versions
DE102004059357A1 (de
DE102004059357B4 (de
Inventor
Anja Dr.rer.nat.habil. Saalbach
Anne Dipl.-Biol. Wetzel
Ulf Dr.rer.nat.habil. Anderegg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Leipzig
Original Assignee
Universitaet Leipzig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Leipzig filed Critical Universitaet Leipzig
Priority to DE102004059357A priority Critical patent/DE102004059357B8/de
Publication of DE102004059357A1 publication Critical patent/DE102004059357A1/de
Application granted granted Critical
Publication of DE102004059357B4 publication Critical patent/DE102004059357B4/de
Publication of DE102004059357B8 publication Critical patent/DE102004059357B8/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
DE102004059357A 2004-12-03 2004-12-03 Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung Expired - Fee Related DE102004059357B8 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE102004059357A DE102004059357B8 (de) 2004-12-03 2004-12-03 Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004059357A DE102004059357B8 (de) 2004-12-03 2004-12-03 Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung

Publications (3)

Publication Number Publication Date
DE102004059357A1 DE102004059357A1 (de) 2006-06-14
DE102004059357B4 DE102004059357B4 (de) 2009-02-12
DE102004059357B8 true DE102004059357B8 (de) 2009-12-03

Family

ID=36500169

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102004059357A Expired - Fee Related DE102004059357B8 (de) 2004-12-03 2004-12-03 Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung

Country Status (1)

Country Link
DE (1) DE102004059357B8 (de)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69315847T2 (de) * 1992-08-21 1998-06-25 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
DE19944995C1 (de) * 1999-07-29 2000-12-21 Gsf Forschungszentrum Umwelt Nachweis einer irreversiblen Schädigung von IgG Antikörpern
DE10242337A1 (de) * 2002-09-09 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Isolierung und/oder Identifizierung neuronaler Stammzellen und Verfahren zur Isolierung und/oder Identifizierung neuronaler Vorläuferzellen
DE69828154T2 (de) * 1997-03-12 2005-06-23 Smithkline Beecham Corp. Anti-alphavbeta3 humanizierte monoklonale antikörper

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69315847T2 (de) * 1992-08-21 1998-06-25 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
DE69828154T2 (de) * 1997-03-12 2005-06-23 Smithkline Beecham Corp. Anti-alphavbeta3 humanizierte monoklonale antikörper
DE19944995C1 (de) * 1999-07-29 2000-12-21 Gsf Forschungszentrum Umwelt Nachweis einer irreversiblen Schädigung von IgG Antikörpern
DE10242337A1 (de) * 2002-09-09 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Isolierung und/oder Identifizierung neuronaler Stammzellen und Verfahren zur Isolierung und/oder Identifizierung neuronaler Vorläuferzellen

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Anne Wetzel et al.,"Human Thy-1 (CD90) on activated endothelial cells is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18)", Journal of Immunology (15. März 2004), Vol. 172, 3850-3859 *
CA AN 125:139735 *
Forschungsbericht der Univ. Leipzig 1999, Dr. Saalbach *
Forschungsbericht der Univ. Leipzig 2003, Dr. Saalbach *
Medline Abstr. AN 96021265 *
Medline Abstr. AN 96021265 CA AN 125:139735 Forschungsbericht der Univ. Leipzig 1999, Dr. Saalbach Forschungsbericht der Univ. Leipzig 2003, Dr. Saalbach Anne Wetzel et al.,"Human Thy-1 (CD90) on activated endothelial cells is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18)", Journal of Immunology (15. März 2004), Vol. 172, 3850-3859

Also Published As

Publication number Publication date
DE102004059357A1 (de) 2006-06-14
DE102004059357B4 (de) 2009-02-12

Similar Documents

Publication Publication Date Title
ATE529420T1 (de) 3-ä(2-ää4-hexyloxycarbonylamino-imino-methyl)- phenylaminoü-methylü-1-methyl-1h-benzimidazol-5 carbonyl)-pyridin-2-yl-aminoü-propionsäure- ethylester-methansulfonat-hemihydrat und dessen verwendung als arzneimittel
NO20055246D0 (no) Heteroaromatisk pentasyklisk forbindelse og medisinsk anvendelse derav
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
EP2103628A4 (de) Monoklonaler anti-claudin-3-antikörper und die behandlung und diagnose von krebs unter dessen verwendung
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
ATE479437T1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
IS8026A (is) Mótefni gegn amýlóíðum, samsetningar, aðferðir ognotkun
DE602004021585D1 (de) 5,7-DIAMINOPYRAZOLOi4,3-D PYRIMIDINE ZUR VERWENDUNG IN DER BEHANDLUNG VON BLUTHOCHDRUCK
DE602005003186D1 (de) Fluorkopolymer und dessen Verwendung
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
ATE365719T1 (de) O-cyclopropyl-carboxanilide und ihre verwendung als fungizide
CY2013039I1 (el) Φθοροϋποκατεστημενη ωμεγα-καρβοξυαρυλ διφαινυλ ουρια για τη θεραπεια και προληψη ασθενειων και καταστασεων
DK1765391T3 (da) Bakterielle præparater til behandlingen af cancer
DE602006000339D1 (de) Substituierte pyridinyl und pyrimidinyl derivate als modulatoren eines metabolismus für die behandlung von damit inzusammenhangstehenden krankheiten
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
IS8142A (is) Læknislyf gagnleg til meðferðar á verkjum
ATE434608T1 (de) Verbindungen, die den glutamatrezeptor verstärken und anwendungen davon in der medizin
ATE447570T1 (de) Pyrimidinderivate zur verwendung als vanilloidrezeptorliganden und deren verwendung bei der behandlung von schmerzen
NL1025839A1 (nl) Chinoline- en chinoxalineverbindingen.
DE112005000151A5 (de) Verwendung von Kern-Mantel-Partikeln
EP1742654A4 (de) Anti-lfl2-antikörper zur diagnose, prognose und behandlung von krebs
ZA200711105B (en) Novel physiological substance nesfatin substance relevant thereto, and use of the substances
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8364 No opposition during term of opposition
8381 Inventor (new situation)

Inventor name: WETZEL, ANNE, DIPL.-BIOL., 04299 LEIPZIG, DE

Inventor name: ANDEREGG, ULF, DR.RER.NAT.HABIL., 04416 MARKKL, DE

Inventor name: SAALBACH, ANJA, DR.RER.NAT.HABIL., 04435 SCHKE, DE

8396 Reprint of erroneous front page
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20130702